Haemorrhagic aspects of thrombolytic therapy.
Samama
M
M
Laboratoire Central d'Hématologie, Hôtel Dieu, Paris, France.
D016255:Anistreplase / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000188:drug therapy; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D016255:Anistreplase; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D001241:Aspirin